Browse diseases

…proved responses to immunotherapy across multiple cancer types. Head and neck squamous cell carcinoma (HNSCC) has frequent amplification of the SWI/SNF subunit ACTL6A, which…

…Background Head and neck squamous cell carcinoma (HNSCC) accounts for 4-7% of all cancers globally with about 50% 5-year…

…ciates with an immune activated ‘hot’ tumor microenvironment.In melanoma, elevated baseline activated CD8+ central memory T cells and pr…

…heckpoint blockade (ICB) therapy has shown promise for treating head and neck squamous cell carcinoma (HNSCC), but only a subset of patients exhibit a meaningful response. H…

…sions TU2218 in combination with Pembrolizumab in patients with HNSCC demonstrated high response rate and manageable toxicity support…

…unique samples. Compared to HPV+ oropharynx tumors, oral cavity HNSCC had significantly higher proportions of NK cells (p = 0.02), an…

…lanatory value in the pathogenesis of CSCC. Comparing CSCC with head and neck squamous cell carcinoma (HNSCC)—which shares histology but responds poorly to PD-1 inhibitors—m…

…er therapies, has led to important progress in the treatment of head and neck squamous cell carcinoma (HNSCC). Yet, a significant proportion of patients with carcinogen-asso…

… biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin…

…tcomes in cancer patients. Based on our preclinical findings in head and neck squamous cell carcinoma (HNSCC), we aim conduct a phase I trial to test the safety of neoadjuva…

… a critical role in the progression and therapeutic response of head and neck squamous cell carcinoma (HNSCC). TOX, a key regulator of T cell exhaustion, has gained attentio…

…er therapies, has led to important progress in the treatment of head and neck squamous cell carcinoma (HNSCC). Yet, a significant proportion of patients with carcinogen-asso…